Buccal drug delivery offers a promising, non-invasive route for the systemic administration of both small-molecule and biologic therapeutics. To date however, its broader clinical utility is limited by poor permeability of the oral mucosa and enzymatic degradation within the oral cavity. Microneedle (MN) technologies are well established in transdermal delivery and provide a compelling strategy to overcome these barriers, yet their application to buccal tissues remains underexplored. This project aims to advance buccal drug delivery through the design, fabrication, and evaluation of highly precise microneedle patches produced using additive manufacturing techniques. These will include two-photon polymerisation (2PP) using the CELLINK Nanoscribe Quantum X bio 3D printer at Aston University, the first of its kind to be installed by Nanoscribe in the UK.
The first objective will engineer microneedle geometries optimised for buccal tissue insertion, mechanical resilience, and release profile. By tailoring microstructures, the study will identify design parameters that enable reliable penetration of the keratinised and non-keratinised regions of the oral mucosa with minimal patient discomfort and risk of adverse effects. To support systematic optimisation, a structured Design of Experiments (DOE) approach will be employed. Material selection will focus on biocompatible, photopolymerisable resins suitable for drug loading or for forming drug-containing matrices.
The second objective is to investigate the capacity of these MN systems to deliver both small-molecule compounds and biologics. Encapsulation strategies, including matrix-loaded, dip-coated, and layered designs, will be evaluated for stability, release kinetics, and compatibility. In vitro permeation studies using buccal models will quantify enhancement in trans-mucosal transport, while analytical assays will assess formulation integrity post-fabrication and post-delivery.
Anticipated project outcomes will demonstrate how 2PP-engineered microneedle patches can significantly enhance buccal delivery of diverse therapeutics. This work will provide a platform to support future translational development of minimally invasive, patient-friendly buccal delivery platforms.
Curti, C., Kirby, D.J. and Russell, C.A., 2020. Current formulation approaches in design and development of solid oral dosage forms through three-dimensional printing. Progress in Additive Manufacturing, 5(2), pp.111-123.
Curti, C., Kirby, D.J. and Russell, C.A., 2021. Stereolithography apparatus evolution: enhancing throughput and efficiency of pharmaceutical formulation development. Pharmaceutics, 13(5), p.616.
Curti, C., Kirby, D.J. and Russell, C.A., 2024. Systematic screening of photopolymer resins for stereolithography (SLA) 3D printing of solid oral dosage forms: Investigation of formulation factors on printability outcomes. International Journal of Pharmaceutics, 653, p.123862.
https://www.greaterbirminghamchambers.com/resource/university-wins-major-funding-for-3d-bioprinter-to-enable-new-research-into-how-the-body-works.html